Bristol Myers Squibb Announces ZENBEXUS In Combination With Daratumumab And Dexamethasone Demonstrates Superior Progression-Free Survival Vs. Standard Of Care In Relapsed And Refractory Multiple Myeloma In Phase 3 EXCALIBER-RRMM Study

Bristol Myers Squibb's (BMS) Zenbexus (iberdomide) met its primary endpoint in a Phase III trial, doubling progression-free survival (PFS) in multiple myeloma patients. The trial showed a median PFS of 42 months for Zenbexus compared to 20 months for standard therapy. The FDA approved Zenbexus for relapsed/refractory multiple myeloma in August 2026. BMS plans to present full results at the American Society of Hematology meeting in December.

Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 trial results for Zenbexus (iberdomide) in multiple myeloma patients. The drug, combined with daratumumab and dexamethasone, showed a 51% reduction in disease progression or death risk, with a median progression-free survival of 42 months. The FDA previously granted accelerated approval for Zenbexus in August. BMY shares were down 1.41% at $58.86 on Thursday.

Bristol Myers Squibb reported positive results from a Phase 3 trial for Zenbexus, a treatment for multiple myeloma. The drug is already FDA-approved for another blood cancer. The trial success could expand Zenbexus's market potential.

Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for its multiple myeloma treatment, showing a 51% reduction in disease progression risk. The company offers a 4.08% dividend yield with a 41% payout ratio and a GF Score of 72/100. Institutional interest is mixed, with some gurus adding and others trimming positions.

Bristol Myers Squibb (BMY) reported that its Phase 3 EXCALIBER-RRMM study met its primary endpoint, showing a 51% reduction in disease progression or death risk for relapsed or refractory multiple myeloma patients treated with ZENBEXUS-based therapy. Median progression-free survival was 42 months compared to 20 months with the comparator regimen, with no new safety concerns noted.

Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for ZENBEXUS (iberdomide) with daratumumab and dexamethasone (ZDd) in relapsed/refractory multiple myeloma. ZDd showed a 51% reduction in disease progression or death risk vs. standard treatment (median PFS 42 months vs. 20 months). The safety profile was consistent with prior findings. Results will be presented at the American Society of Hematology meeting.